India's Patients Are Its Strongest Pharma Asset: Trading Trial Cohorts for Fair Orphan-Drug Prices
In The Hindu's opinion pages, researchers from the Tata Institute for Genetics and Society have proposed a policy framework to make India a hub for rare-disease drug trials and manufacturing. It comes as families continue to crowdfund crore-scale gene therapies that the government's ₹50 lakh support cap cannot cover.